Compare WLDN & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | ENOV |
|---|---|---|
| Founded | 1964 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Fluid Controls |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2006 | 2008 |
| Metric | WLDN | ENOV |
|---|---|---|
| Price | $80.06 | $25.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $114.50 | $47.38 |
| AVG Volume (30 Days) | 248.6K | ★ 670.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $273,352,000.00 | N/A |
| Revenue This Year | N/A | $6.36 |
| Revenue Next Year | $12.05 | $5.31 |
| P/E Ratio | $22.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.60 | $21.00 |
| 52 Week High | $137.00 | $36.82 |
| Indicator | WLDN | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 61.35 |
| Support Level | $74.39 | $21.37 |
| Resistance Level | $85.35 | $26.41 |
| Average True Range (ATR) | 3.89 | 1.04 |
| MACD | 1.25 | 0.31 |
| Stochastic Oscillator | 55.52 | 87.56 |
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.